Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid

AIDS. 2002 Sep 6;16(13):1830-2. doi: 10.1097/00002030-200209060-00019.

Abstract

Genotypic resistance to antiretroviral drugs was analysed in plasma from 57 acute or recent HIV seroconverters in Madrid. The overall prevalence of drug-associated primary resistance mutations was 25.8% in 1997-1999, but declined to 3.8% in 2000-2001. The lower rate in recent years suggested that most new HIV infections derive from viraemic individuals unaware of their HIV- positive status, rather than from those failing antiretroviral treatment. Drug-resistance testing is thus not required before beginning antiretroviral therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / pharmacology
  • Drug Resistance, Viral / genetics*
  • Female
  • Genotype
  • HIV / drug effects*
  • HIV / genetics
  • HIV Infections / epidemiology*
  • HIV Infections / virology*
  • HIV Protease / genetics
  • HIV Protease Inhibitors / pharmacology
  • HIV Reverse Transcriptase / genetics
  • HIV Seropositivity*
  • Humans
  • Male
  • Mutation
  • Reverse Transcriptase Inhibitors / pharmacology
  • Spain / epidemiology

Substances

  • Anti-HIV Agents
  • HIV Protease Inhibitors
  • Reverse Transcriptase Inhibitors
  • HIV Reverse Transcriptase
  • HIV Protease